Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 71-80 of 293 for

Edit search filters
  1. Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

    La Crosse, WI, Albert Lea, MN, Eau Claire, WI, Mankato, MN, Rochester, MN

  2. Remote Monitoring for Lifestyle Changes in Patients with Lung Cancer Related Fatigue

    Rochester, MN

  3. Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

    Eau Claire, WI, La Crosse, WI, Mankato, MN, Rochester, MN, Jacksonville, FL

  4. A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. A Study to Evaluate the Effectiveness and Safety of rAd-IFN Administered With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma

    Rochester, MN

  6. A Study to Compare Radiation Therapy + Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer

    Albert Lea, MN, Scottsdale/Phoenix, AZ, La Crosse, WI, Rochester, MN

  7. Sacituzumab Tirumotecan (MK-2870) In Combination With Pembrolizumab Versus Pembrolizumab Alone In Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. A Study To Evaluate Telisotuzumab Vedotin (ABBV-399) In Subjects With Previously Treated C-Met+ Non-Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. Taletrectinib Phase 2 Global Study In ROS1 Positive NSCLC

    Rochester, MN

  10. A Study Of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody In Participants With Advanced Or Metastatic NSCLC

    Rochester, MN

.

Mayo Clinic Footer